Search

Search bills, members, committees and pages...

Sign In

H.R. 1796

U.S. House•In House Committee

Summary

H.R. 1796, the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025, was introduced in the House on Mar 3, 2025 by Rep. John James (R) with 6 co-sponsors. It was referred to Energy And Commerce, and last saw action on Mar 3, 2025: Referred to the House Committee on Energy and Commerce.

Record

Text

H.R. 1796 has 6 co-sponsors.

hb1796/introduced-in-house.txt
119 HR 1796 IH: Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
 U.S. House of Representatives
 2025-03-03
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  1st Session  H. R. 1796  IN THE HOUSE OF REPRESENTATIVES   March 3, 2025   Mr. James  (for himself,  Mr. Veasey ,  Mr. Carter of Louisiana ,  Mr. Davis of Illinois , and  Mrs. Kiggans of Virginia ) introduced the following bill; which was referred to the  Committee on Energy and Commerce    A BILL
To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.
1.
Short title
This Act may be cited as the   Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025  .
2.
Sickle cell disease treatment prevention and treatment
(a)
In general
Section 1106(b) of the Public Health Service Act ( 42 U.S.C. 300b–5(b) ) is amended—
(1)
in paragraph (1)(A)(iii), by striking  prevention and treatment of sickle cell disease  and inserting  treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease ;
(2)
in paragraph (2)(D), by striking  prevention and treatment of sickle cell disease  and inserting  treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease ;
(3)
in paragraph (3)—
(A)
in subparagraph (A), by striking  enter into a contract with  and inserting  make a grant to, or enter into a contract or cooperative agreement with, ; and
(B)
in subparagraph (B), in each of clauses (ii) and (iii), by striking  prevention and treatment of sickle cell disease  and inserting  treatment of sickle cell disease and the prevention and treatment of complications of sickle cell disease ; and
(4)
in paragraph (6), by striking  $4,455,000 for each of fiscal years 2019 through 2023  and inserting  $8,205,000 for each of fiscal years 2025 through 2029 .
(b)
Sense of Congress
It is the sense of Congress that further research should be undertaken to expand the understanding of the causes of, and to find cures for, heritable blood disorders, including sickle cell disease.

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

  1. Introduced2025-03-03
  2. Passed House
  3. Passed Senate
  4. Conference
  5. To President
  6. Became Law

To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program.

Sponsors

Rep. John James (R) sponsors H.R. 1796, and 6 members have co-sponsored it, 4 of them from the day it was introduced.

Committees

H.R. 1796 went before 1 committee: Energy and Commerce.

Energy and Commerce
Energy and Commerce
Referred To · Mar 3, 2025 · 1,636 Bills

Actions

H.R. 1796 has taken 2 actions since Mar 3, 2025.

ChamberAction
Mar 3, 2025
House
Introduced in House
Mar 3, 2025
House
Referred to the House Committee on Energy and Commerce.Energy and Commerce Committee

Votes

H.R. 1796 has not gone to a roll call.

4 bills are related to H.R. 1796.

Titles

H.R. 1796 goes by 3 titles, 1 of them short titles.

  • Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 — Display Title
  • Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 — Short Title(s) as Introduced
  • To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program. — Official Title as Introduced

Lobbying

7 clients hired 6 firms and 15 registered lobbyists who named H.R. 1796 in 28 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Health Issues, Budget/Appropriations, Medicare/Medicaid, Trade (domestic/foreign), Insurance, Agriculture, Medical/Disease Research/Clinical Labs, Pharmacy.

Clients

Who paid to be heard, by how many filings named the bill.

ClientBusinessStateFirmsFilingsReported
FULCRUM THERAPEUTICSRare disease biopharma companyMassachusetts16$270K
TERUMO BCT, INC.Medical technology companyColorado16—
LEAVITT PARTNERS, LLC ON BEHALF OF SICKLE CELL DISEASE PARTNERSHIPconsulting firm on behalf of multi-sector collaboration of health care stakeholdersMichigan15$100K
SICKLE CELL DISEASE ASSOCIATION OF AMERICAnational organization dedicated to supporting people living with sickle cell diseaseMaryland15$100K
SICK CELLSNational Sickle Cell AdvocacyIllinois14$120K
NATIONAL BLEEDING DISORDER FOUNDATION (FKA NATIONAL HEMOPHILIA FOUNDATION)Nonprofit supporting patients with inheritable bleeding disorders.New York11$50K
NEMOURS FOUNDATION - A FLORIDA NOT-FOR-PROFIT CORPORATION—District of Columbia11—

Firms

Registrants who filed on the bill, by filings.

RegistrantClientsFilingsReported
ARTEMIS POLICY GROUP LLC26$150K
TERUMO BCT, INC.16—
THE MCMANUS GROUP16$270K
OGR15$100K
INDIGO HILL STRATEGIES14$120K
THE NEMOURS FOUNDATION - A FLORIDA NOT-FOR-PROFIT CORPORATION11—

Lobbyists

Named on the filings that cite the bill.

LobbyistFirmsClientsFilings
ELLEN RIKER126
JOHN MCMANUS116
LATOYA THOMAS116
LESLIE BRADY126
JEROME MURRAY115
RYANN HILL114
TAYLOR TURNER114
LAWREN GEER113
ABIGAIL SMITH112
EBONY SLAUGHTER-JOHNSON112
MARY DARCEY112
DANIELLA GRATALE111
JOHANNA GRAY111
KATHLEEN OSGOOD111
MIRIAM GOLDSTEIN111

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

ClientRegistrantPeriodReportedDocument
NEMOURS FOUNDATION - A FLORIDA NOT-FOR-PROFIT CORPORATIONTHE NEMOURS FOUNDATION - A FLORIDA NOT-FOR-PROFIT CORPORATION2025 first_quarter$247.5K1st Quarter - Report
FULCRUM THERAPEUTICSTHE MCMANUS GROUP2026 second_quarter$60K2nd Quarter - Termina…
FULCRUM THERAPEUTICSTHE MCMANUS GROUP2026 first_quarter$50K1st Quarter - Report
NATIONAL BLEEDING DISORDER FOUNDATION (FKA NATIONAL HEMOPHILIA FOUNDATION)ARTEMIS POLICY GROUP LLC2025 first_quarter$50K1st Quarter - Report
FULCRUM THERAPEUTICSTHE MCMANUS GROUP2025 fourth_quarter$40K4th Quarter - Report
FULCRUM THERAPEUTICSTHE MCMANUS GROUP2025 third_quarter$40K3rd Quarter - Report
FULCRUM THERAPEUTICSTHE MCMANUS GROUP2025 second_quarter$40K2nd Quarter - Report
FULCRUM THERAPEUTICSTHE MCMANUS GROUP2025 first_quarter$40K1st Quarter - Report
SICK CELLSINDIGO HILL STRATEGIES2026 second_quarter$30K2nd Quarter - Report
SICK CELLSINDIGO HILL STRATEGIES2026 first_quarter$30K1st Quarter - Report
SICK CELLSINDIGO HILL STRATEGIES2025 fourth_quarter$30K4th Quarter - Report
SICK CELLSINDIGO HILL STRATEGIES2025 third_quarter$30K3rd Quarter - Report
TERUMO BCT, INC.TERUMO BCT, INC.2026 second_quarter$20K2nd Quarter - Report
LEAVITT PARTNERS, LLC ON BEHALF OF SICKLE CELL DISEASE PARTNERSHIPOGR2026 second_quarter$20K2nd Quarter - Report
SICKLE CELL DISEASE ASSOCIATION OF AMERICAARTEMIS POLICY GROUP LLC2026 first_quarter$20K1st Quarter - Report
TERUMO BCT, INC.TERUMO BCT, INC.2026 first_quarter$20K1st Quarter - Report
LEAVITT PARTNERS, LLC ON BEHALF OF SICKLE CELL DISEASE PARTNERSHIPOGR2026 first_quarter$20K1st Quarter - Report
SICKLE CELL DISEASE ASSOCIATION OF AMERICAARTEMIS POLICY GROUP LLC2025 fourth_quarter$20K4th Quarter - Report
TERUMO BCT, INC.TERUMO BCT, INC.2025 fourth_quarter$20K4th Quarter - Report
LEAVITT PARTNERS, LLC ON BEHALF OF SICKLE CELL DISEASE PARTNERSHIPOGR2025 fourth_quarter$20K4th Quarter - Report

Classification

The Congressional Research Service files H.R. 1796 under Health, one of its 31 policy areas, and gives it 6 legislative subjects.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 1796’s is Health.

hr1796/policy-areas.txt
HealthAgriculture and FoodAnimalsArmed Forces and National SecurityArts, Culture, ReligionCivil Rights and Liberties, Minority IssuesCommerceCongressCrime and Law EnforcementEconomics and Public FinanceEducationEmergency ManagementEnergyEnvironmental ProtectionFamiliesFinance and Financial SectorForeign Trade and International FinanceGovernment Operations and PoliticsHousing and Community DevelopmentImmigrationInternational AffairsLabor and EmploymentLawNative AmericansPublic Lands and Natural ResourcesScience, Technology, CommunicationsSocial WelfareSports and RecreationTaxationTransportation and Public WorksWater Resources Development

Legislative Subjects

H.R. 1796 carries 6 of CRS’s legislative subjects, from Blood and blood diseases to Research administration and funding.

hr1796/subjects.txt
Blood and blood diseasesGeneticsHealth promotion and preventive careHereditary and development disordersMedical researchResearch administration and funding

Source: congress.gov · legiscan.com